Elicio Therapeutics, Inc (ELTX)
NASDAQ:ELTX
Want to see ELTX full AI Analyst Report?
Top Page
Elicio Therapeutics
(NASDAQ:ELTX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$4.00
▼(-70.48% Downside)
Action:Reiterated
Date:06/16/26
The score is primarily weighed down by weak financial performance (no revenue, sizable losses, heavy cash burn, and negative equity implying elevated financing/dilution risk). Technicals are also bearish with the stock far below major moving averages despite oversold RSI. Valuation is constrained by ongoing losses and no dividend, while the latest corporate update adds risk after missing the Phase 2 primary endpoint despite some subgroup and safety positives.
Positive Factors
Mechanism-confirmed immune activity
Correlation between mKRAS-specific T-cell responses and better disease-free survival demonstrates on-target biological activity and a measurable pharmacodynamic biomarker. That durable mechanistic signal supports patient selection, de-risks later studies, and strengthens partner/license interest over months to years.
Negative Factors
No revenue; large cash burn
Persistent negative operating and free cash flow around -$38.5M TTM means the company relies on external capital to sustain R&D and trial execution. Over a multi-month horizon this constrains optionality, increases financing urgency, and may delay programs absent fresh funding or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Mechanism-confirmed immune activity
Correlation between mKRAS-specific T-cell responses and better disease-free survival demonstrates on-target biological activity and a measurable pharmacodynamic biomarker. That durable mechanistic signal supports patient selection, de-risks later studies, and strengthens partner/license interest over months to years.
Read all positive factors
Elicio Therapeutics (ELTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$283.43M
Dividend YieldN/A
Average Volume (3M)142.90K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS Growth43.68%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.36
Shares Outstanding19,086,080
10 Day Avg. Volume155,296
30 Day Avg. Volume142,903
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-720.63
Enterprise Value/Ebitda-5.53
Forecast
1Y Price Target
$23.33Price Target Upside72.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.95
Revenue Forecast (FY)N/A
Elicio Therapeutics Business Overview & Revenue Model
Company Description
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an A...
How the Company Makes Money
null...
Elicio Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.31M |
| Gross Profit | -289.00K | -1.13M | -1.18M | -1.17M | -1.06M | 27.08M |
| EBITDA | -37.68M | -37.31M | -50.27M | -32.97M | -23.55M | -51.92M |
| Net Income | -40.19M | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
Balance Sheet | ||||||
| Total Assets | 22.69M | 25.86M | 28.18M | 27.15M | 22.66M | 96.51M |
| Cash, Cash Equivalents and Short-Term Investments | 14.95M | 18.56M | 17.62M | 12.89M | 7.80M | 88.76M |
| Total Debt | 14.34M | 14.51M | 26.04M | 6.92M | 7.48M | 4.66M |
| Total Liabilities | 24.13M | 24.23M | 39.49M | 15.77M | 13.75M | 15.01M |
| Stockholders Equity | -1.44M | 1.64M | -11.31M | 11.37M | 8.91M | 81.51M |
Cash Flow | ||||||
| Free Cash Flow | -38.49M | -36.97M | -37.16M | -32.76M | -22.83M | -24.46M |
| Operating Cash Flow | -38.48M | -36.95M | -37.07M | -32.69M | -22.18M | -23.94M |
| Investing Cash Flow | -16.00K | -16.00K | -84.00K | -32.00K | -654.00K | -525.36K |
| Financing Cash Flow | 34.39M | 36.70M | 42.32M | 38.61M | 21.20M | 19.39M |
Elicio Therapeutics Technical Analysis
Negative
13.55
Price Trends
11.24
Negative
10.68
Negative
10.04
Negative
Market Momentum
0.17
Positive
27.56
Positive
46.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Negative. The current price of 13.55 is above the 20-day moving average (MA) of 11.48, above the 50-day MA of 11.24, and above the 200-day MA of 10.04, indicating a bearish trend. The MACD of 0.17 indicates Positive momentum. The RSI at 27.56 is Positive, neither overbought nor oversold. The STOCH value of 46.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTX.
Elicio Therapeutics Risk Analysis
Elicio Therapeutics disclosed 91 risk factors in its most recent earnings report. Elicio Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elicio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $192.89M | 5.48 | 47.72% | ― | 163.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $158.11M | -2.50 | -339.38% | ― | ― | 17.64% | |
46 Neutral | $55.20M | -1.15 | -127.30% | ― | ― | 49.74% | |
41 Neutral | $283.43M | -1.85 | -2748.16% | ― | ― | 43.68% |
* Healthcare Sector Average
ELTX
Elicio Therapeutics
4.08
-3.63
-47.05%
CGEN
Compugen
2.02
0.37
22.42%
MCRB
Seres Therapeutics
5.62
-1.88
-25.07%
MIST
Milestone Pharmaceuticals
1.31
-0.41
-23.84%
ACTU
Actuate Therapeutics, Inc.
2.05
-6.32
-75.51%
Elicio Therapeutics Corporate Events
Business Operations and Strategy
Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan
Negative
Jun 15, 2026
On June 15, 2026, Elicio Therapeutics reported topline results from its randomized Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma following standard locoregional therapy. The study did not me...
Business Operations and StrategyPrivate Placements and Financing
Elicio Therapeutics Launches New $100 Million ATM Program
Neutral
Mar 16, 2026
On March 16, 2026, Elicio Therapeutics entered into a new at-the-market equity offering program of up to $100 million in common stock through B. Riley Securities, JonesTrading Institutional Services and Ladenburg Thalmann, giving the biotech flexi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.